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                                   INTRODUCTION 
Cardiac function and kidney function are closely interconnected and a 
synergistic relationship exists between these organs. Dysfunction of heart  often 
leads to a deterioration of function of the kidney. This clinical entity has been 
defined as cardio renal syndrome. 
CRS type1 or acute CRS is described by rapid worsening of cardiac 
function leading to acute kidney injury. It is most common and rapid 
deterioration of pulmonary edema, acutely decompensated chronic cardiac 
failure, cardiogenic shock and primarily right heart failure leading to acute renal 
dysfunction. 
Approximately one third of the ADHF patients develop AKI as defined 
by an increase in serum creatinine of  >0.3 mg/dl. In patient with cardiogenic 
shock, the incidence of AKI can exceed 70%.  The development of WRF in this 
setting usually associated with high mortality risk. 
The pathophysiology of WRF in ADHF is complex and multifactorial. 
Major contributing mechanisms include congestion, haemodynamic factors and 
neurohormonal activation. Baseline chronic kidney disease, diabetes mellitus, 
prior cardiac failure and initial presentation with systemic hypertension are 
established risk predictors for CRS type 1.  
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Hyponatremia is the most common electrolyte disorder in hospitalized 
patients  and is commonly observed in ADHF.  Hyponatremia in patients with 
heart failure is an independent risk factor of mortality and repeated admission 
for decompensation. 
The prevalence of hyponatremia and volume overload is high in 
hospitalized patients with worsening heart failure than outpatients.  
Hyponatremia , the volume overload status with venous congestion of kidney,  
neurohormonal activation,  vasoconstriction , and the reduced renal blood flow  
make the kidneys more susceptible to develop WRF. 
Hyponatremia was defined as serum sodium <136 mmol/L .    WRF was 
defined based on the maximal increase of   >0.3 mg/dl in serum creatinine from 
the admission value at any time during the hospital stay.  
Patients with worsening renal function have a decreased ability for 
sodium and water excretion thus placing them at an increased risk of developing  
hyponatremia. Efforts to maintain normal renal function including blood 
pressure control, limiting use of nephrotoxic medication and avoiding excessive 
diuresis may help to limit the risk of hyponatremia. 
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AIMS AND OBJECTIVES 
1. To study the prevalence of hyponatremia in acute decompensated heart 
failure patients 
 
2. To evaluate the association between hyponatremia and worsening renal 
function  
 
3. To predict morbidity and mortality in CRS type 1 
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REVIEW OF LITERATURE 
 
 
Water is important constituent in the body comprising about 50% of body 
weight in females and 60% in males.It is divided in to ECF(55 -75%) and 
ICF(25-45%).ECF is further divided into intravascular (plasma) and 
extravascular (interstitial) fluid. The concentration of solute or particle  in the 
fluid is known as osmolality(mOsm/kg).  Important ECF particles are Na,Cl and 
Hco3 and ICF particles are potassium,organic esters. 
 
 Water balance is regulated by vasopressin secretion ,water intake and 
renal water transport to maintain osmolality between 280-295 mOsm/kg. 
Synthesis of vasopressin occurs in magnocellular neurons in hypothalamus. 
Distal axons of these neurons project into the posterior pituitary, from which 
vasopressin is secreted in the body circulaton. 
 
           There is linear relationship between vasopressin and serum osmolality. 
Blood pressure and blood volume are also direct stimuli for AVP. Half life of 
AVP is 10-20 minutes. 
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  Sodium balance  
           Normal sodium concentration in plasma is more than 140meq/l.sodium is 
the principal osmole ,present in the extracellular fluid and maintaining the ECF 
volume.Regulation of blood pressure and osmotic equilibrium.sodium 
contration in ECF is maintainted by the action of Na/K ATP ase. Water can 
easily cross the cell membranes to maintain normal tonicity between ECF and 
ICF. Sodium cannot freely cross the cellmembrane. It requires energy 
dependent pump to cross  cell membrane.  Plasma sodium concentration is 
determind by multiple factors including osmolality, tonicity of plasma, sodium 
intake, renin angiotensin system, total potassium concentration and water.  
 
   Plasma osmolality is determained by mainly by serum sodium and minor 
contributors are glucose and blood urea nitrogen. 
 
 Plasma osmolality is calculated by following formula: 
                PLASMA OSMOLALITY =( 2×Na)+(glucose/18)+(BUN/2.8) 
         The sodium  is multiplied by two to account for the accompanying anions 
like bicarbonate and chlorides for electrical neutrality. 
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            The corrections are  made in the glucose concentration and blood urea 
nitrogen to convert mg/dl into mmol/1.  Urea is lipid-soluble.It equilibrates across 
the cell membranes and it is ineffective osmole and does not contribute to fluid 
distribution, and therefore it is rejected from calculation of effective plasma 
osmolality . 
 
Effective plasma osmolality = (2x [Na+]) + ([glucose]/18).Normal plasma 
osmolality varies between 280 and 290mOsm/l. A discrepancy between the 
measured and calculated osmolality is referred to as an osmolal gap. A increased 
concentration of osmotically active molecules present in plasma such as ethanol, 
mannitol, methanol, ethylene glycol and isopropyl alcohol leads to significant 
osmolal gap. 
 
Average sodium intake is 4-5 g per day (173-217 mmol/day). Sodium 
chloride is available as table salt, which dissolves in water to give sodium and 
chloride ions. Sodium is 0.39 weight of sodium chloride. So 1 g of table salt or salt 
tablets contains roughly 400 mg of sodium. One teaspoon of table salt comprises 
about 6 g of NaCl with approximately 2.4 g (104mmol) sodium. 
 
One gram of sodium gives  43 mEq of sodium ions, whereas 1 g of sodium 
chloride gives 17 mEq of sodium ions. The  amount of filtered  sodium load 
(25,250) is the product of GFR and sodium cancentration in plasma. For 
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maintaining sodium balance with a dietary intake of sodium nearly 200 mmol or 
3.2 g/day, a total of 25,000 mmol (about 99.6% of the filtered load) should be 
reabsorbed. 
 
          Proximal tubule of kidney  reabsorbs about 60-70% of the filtered sodium . 
Ascending limb of the loop of Henle reabsorbs about 20-30%. The  remaining 
sodium  about 5-10% is reabsorbed in the distal tubule and collecting duct, under 
the influence of aldosterone. 
 
        Sudden decrease in blood volume is recognised by mechanoreceptors present 
in the left ventricle, carotid sinus, aortic arch and renal afferent arterioles leading to 
activation of the RAA system, stimulation of thirst and non osmotic release of 
arginine vasopressin. Juxtaglomerular cells of the kidney produce and secretes 
renin. Renin isoenzymes present in many tissues, including brain, adrenals, 
vascular beds, uterus and placenta. 
 
Renin cleaves its substrate angiotensinogen to produce  the angiotensin I, 
which is converted to angiotensin II by angiotensin I-converting enzyme. 
Angiotensin II stimulates aldosterone secretion from the adrenal cortex and also 
partially suppresses renin secretion by a direct effect on the juxtaglomerular cells. 
Aldosterone increases sodium reabsorption and potassium excretion in the distal  
tubule and the collecting duct of the nephron, the site where ADH regulates the 
rate of water reabsorption also. 
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 Tonicity refers to the effect of a solution on the cell volume. An isotonic 
solution doesn’t have any effect on cell volume, whereas   hypotonic  solutions 
increase and hypertonic solution decrease cell volume. Infusion of isotonic saline 
causes volume expansion without changing the plasma osmolality. And the steady 
state is restored by renal sodium excretion , ADH release and thirst are not altered. 
On the other hand, intake of large quantities of Nacl without water (e.g. 
consumption of salted pretzels, potato chips or peanuts) results in an elevation in 
the plasma osmolality and stimulation of thirst and ADH secretion leading to ECV 
expansion. ECF volume expansion will suppress the RAA system, resulting in 
increased urinary sodium excretion. Thus, the maintenance of the ECV is 
dependent on the regulation of sodium balance, while plasma osmolality is largely 
maintained by the regulation of water balance. 
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                                               HYPONATREMIA 
 
       Hyponatremia is usually associated with increase in circulating AVP and/ or 
increased renal sensitivity to AVP. The underlying  pathophysiology for increased 
or inappropriate AVP response differs in patient with ECF volume status. 
 
       Hyponatremia is classified into three groups 
1. Hypovolemic hypontremia 
2. Euvolemic  hyponatremia 
3. Hypervolemic hyponatremia 
 
HYPOVOLEMIC HYPONATREMIA 
   
       Hypovolemia facilitates neurohumoral activation and increases the circulating 
levels of AVP. The increase in circulating of AVP preserve blood pressure via  
receptor mediated action like vascular and baroreceptor V1a and increase 
reabsorption of water through V2 receptor present in the renal tubules. Activation 
of V2 receptor may lead to hyponatremia in the setting of increased  free water 
intake. 
           Hypovolemic hyponatremia causes are  classified into renal and extra renal . 
Extra renal causes are vomiting, diarrhea, tube drainage and insensible water and 
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sodium loss like burns, sweating in the absence of adequate water intake. Renal 
causes are diuretic excess, ketonuria ,  mineralo corticoid deficiency , salt losing 
nephropathy, osmotic diuresis and cerebral salt wasting disorder. In both causes 
urine sodium concentration   differs  but blood volume is low  in each condition. 
           Clinical finding of extracellular volume deficit such as flat neck veins, 
decreased skin turgor, dry mucous membranes, orthostatic hypotension and 
tachycardia. 
          Measurement  of  the  urinary  Na+  concentration  is  useful  in  assessing 
 
whether losses are renal/extra renal in origin. Urinary Na+ concentration of <20 
mEq/1 reflects a normal renal response to hypovolemia and points to an extra 
renal source of Na+ loss. In patients with hypovolaemic hyponatraemia, urinary 
 
Na+ concentration in excess of 20 mEq/1, it indicate reanl origin. 
 
 HYPOVOLEMIC HYPONATREMIA 
Renal cause(U Na>20) Extra renal cause(U Na<20) 
Diuretic excess 
Cerebral salt wasting 
Mineralo corticoid deficiency 
Ketonuria 
Vomiting 
Diarrhea 
Burns  
Pancreatitis 
Trauma 
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          Hypovolaemic hyponatraemia can be intensified when fluid losses are 
replaced with hypotonic fluids. When isotonic saline is used, it abolishes the 
stimulus for ADH release, thereby  permitting the excess water to be excreted. This 
effect may normalise the plasma sodium concentration quickly and may be adverse 
in patients with chronic hyponatraemia (> 48 h). Administration of desmopressin 
or hypotonic solutions may be useful to slow the rate of sodium correction in these 
patients. 
EUVOLEMIC HYPONATREMIA 
          Euvolemic hyponatremia cccurs in moderate to severe hypothyroidism and 
also occurs in pituitary dieease and with predominant glucocorticoid deficiency in  
Secondary  failure. Glucocorticoid   have negative feedback action on AVP release 
by acting on posterior pituitary. So hydrocortisone replacement will normalize the 
AVP  response to osmolality.    
         Other important causes are SIADH , drugs and stress .The mechanism of 
hyponatremia in SIADH is persistant intake of free water at serum osmolalities that 
are lower than the usual threahold for thirst. Patient with SIADH have four 
different pattern of AVP release, 
      1. unregulated and erratic AVP  release with no correlation between serum 
osmolality and blood AVP levels 
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     2. some patients fails to suppress the AVP release at deceased serum osmolality 
with normal response curve to hyperosmolar state 
     3. some patients have reset osmostat with left shifted osmotic response curve 
and lower osmolality threshold 
     4.some patient have gain in function in renal warer reabsorption or other 
circulating substances like antidiuretics without detectable circulating AVP 
Causes of euvolemic hyponatremia 
EUVOLEMIC HYPONATREMIA 
Glucocorticoid deficiency                stress ,drugs 
Hypothyroidism                                 SIADH 
 
Decreased GFR and renal blood flow has been shown to be associated with 
Hypothyroidism. ADH level is elevated with severe hypothyroidism, and thyroxine 
treatment normalize  the elevated ADH levels. The impaired water excretion in this 
disease  is being mediated by the increased  ADH combined with decreased distal 
fluid delivery. 
         Continued ADH release  and excessive hypotonic fluid intake contributes to 
the exercise-associated hyponatraemia (EAH) seen after endurance exercise (e.g. 
triathlon events and marathons) . Hypovolaemia because of sweat losses, severe 
exercise pain and stress   constitutes the non-osmotic stimuli for the ADH secretion 
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in endurance athletes .  Clinical manifestations like dizziness, nausea and vomiting 
to seizures, coma and death are  due to acute hyponatremia seen in exercise 
associated hyponatremia. 
Fluid restriction and observation until the onset of a spontaneous diuresis is 
the initial  management protocol for  patients with mild to moderate symptoms 
Where as hypertonic saline can be given for those with severe neurological 
symptoms till the recovery from neurological symptoms. Prevention of these 
conditions can be done by training the endurance athletes to take fluids according 
to thirst during the race. 
            Primary polydipsia also comes under euvolemic hyponatremia. Water 
consumption in excess of 10 to 151 a day has been seen in many patients with 
chronic psychiatric illnesses notably schizophrenia .Suppression of ADH secretion 
occurs as a result of this excess water consumption and patient begins to excrete 
dilute urine (osmolality nearly 50mosm/kg). A defect in regulation of thirst 
centrally possibly plays a pivotal role in the pathogenesis of polydipsia. 
Acutely psychotic patients are at an increased risk for developing 
hyponatraemia and treatement with some antipsychotic medications also add on 
the risk by increasing thirst through anticholinergic side effects. Augmented 
vasopressin release can be seen in schizophrenic patients with hyponatraemia 
during psychotic exacerbations. 
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HYPERVOLEMIC HYPONATREMIA 
          Patient with hypervulemic hyponatremia have increased total body Na, Cl 
but greater increase in total body water exceeds the sodium concentration in 
plasma which leads to hyponatremia. It is classified into two groups by urine 
sodium concentration. 
CAUSES 
U Na>20 U Na<20 
Acute or chronic renal failure Nephrotic syndrome 
Cirrhosis 
Cardiac failure 
 
  The main pathophysiology in this disorder is decrease in arterial 
filling and circulating integrity . The degree of hyponatremia gives gives an 
indirect index of   neurohumoral activation and essential prognostic indicator in 
hypervolemic hyponatremia. 
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            Hyponatremia is commonly occurs in patient with very low intake of 
dietary solutes. Classically it happens in alcoholics whose main nutrient is beer, 
called as beer potomania. Beer  contains very low protein and salt content.extreme 
vegetarian diet also contains low salt and proteon content. 
             Hyponatraemia of unknown aetiology should prompt a work up for 
neuroendocrine amine precursor uptake and decarboxylating (APUD) tumours as 
well as oat cell, breast and ovarian tumours that are often difficult to detect. 
Infection like HIV, hepatitis C , cytomegalo vivus  and toxoplasmosis are some of 
the causes of hyponatremia. 
 
DRUGS CAUSING HYPONATREMIA 
Thiazides, Amiodarone, 
clonidine, ACE  
inhibitors, lorcainide, 
Aldosterone Propafenone, 
antagonists, Theophylline, 
Amiloride, Loop  
diuretics, Terlipressin, 
Methyldopa, 
 
Unfractionated 
Amlodipine, Heparin 
 (aldosterone 
 antagonist) 
 
Cyclophosphamide, Azithromycin 
Vincristine, Trimethoprim- 
Vinblastine sulfamethoxazole,
Cisplatin, 
          
ciprofloxacin, 
 
Hydroxyurea, 
cefoperazone/ 
 
Melphalan 
Sulbactam, 
 
 
Tacrolimus,
Methotrexate, 
interferon a and y, 
levamisole,  
16 
 
 
 
 
17 
 
Clinical features of hyponatraemia 
            Most  patients  with hyponatremia may appear asymptomatic, severe  
symptomatic hyponatremia is a medical emergency that needs immediate 
treatment. Clinical features  depend  on several factors and vary between 
individual. The rate of reduction in serum sodium concentration, age of the patient, 
and the volume of extra cellular fluid (ECF) all alter the clinical presentation. 
CNS symptom 
       Most of the clinical features are related  to dysfunction of the central nervous 
system and are more evident when the decline of serum sodium concentration is 
more or rapid.  Non-neurologic features of hyponatremia are fatigue, thirst, 
weakness, cramping, nausea, vomiting, bloating, swelling, and tightness of the 
hands and feet. Most patients with a serum sodium level more than 125 mEq/L or 
with chronic hyponatremia do not present with neurologic symptoms, because of 
volume adaptation by the brain. 
Gastro intestinal features, such as nausea and vomiting, are most common in 
patients with serum sodium concentration between 125 and 130 mEq/L. Acute 
hyponatremia (<2 days in duration) in a previously asymptomatic young adult can 
cause severe central nervous system symptoms even at serum sodium 
concentration between 125 and 130 mEq/L. Once the sodium concentration falls 
below 125 mEq/L, neurologic symptoms predominate. Headache, muscle cramps, 
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reversible ataxia, psychosis, lethargy, restlessness, disorientation,  anorexia, and 
agitation are symptoms seen in patients with serum sodium concentration below 
125 mEq/L. 
         Clinical signs include abnormal sensorium hypothermia, depressed   deep 
tendon reflexes, pseudobulbar palsy, and Cheyne-Stokes respiration.  
Complications of severe hyponatremia 
          If  hyponatremia develops rapidly, it cause  seizures, coma, brainstem 
herniation, respiratory depression, permanent brain damage, and death. These 
complications primarily due to  hyponatremia induced cerebral edema, which is 
most commonly seen in patients undergone surgery or in patient with primary 
polydipsia. Menstruating women are also at increased  risk of severe neurologic 
features associated with hyponatremia. 
           Clinically important hyponatremia is a particular challenge in patients with 
acute neurologic symptoms  such as cerebral salt-wasting syndrome, syndrome of 
inappropriate antidiuretic hormone secretion (SIADH), anoxic or traumatic brain 
injury, or subarachnoid hemorrhage, since the presentations can overlap 
significantly. 
           Difference between acute and chronic hyponatraemia is clinically essential 
because chronic hyponatraemia is extraordinarily well-tolerated, even at very low 
concentration of serum sodium, and overly aggressive therapy can cause serious 
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neurological problem. Aggressive initial management is essential in patients with 
acute severe   symptomatic hyponatraemia, which may potentially leads to 
irreversible neurological disease  and death. 
         Hyponatraemia is refered as acute when it develops within 48 h of prior 
normal plasma sodium concentration. Acute hyponatraemia occurs in patient  with 
intake of large amount of hypotonic fluids (postoperative patients, marathon 
runners) and also in patient using  'ecstasy' (3,4-memylene dioxy meth 
amphetamine, MDMA). As a result of osmotic effect, water enters intracellularly 
and results in cerebral oedema. Eventually, the extracellular water is moved into  
the cerebrospinal fluid, and cerebral edema gradually decreases by extruding 
sodium and potassium salts and certain organic solutes called osmolytes. 
        Hyponatraemia is refered as chronic if it develops gradualy  and persists for 
greater than 48 h. Patients with chronic slow onset hyponatraemia are typically 
symptoms free because of  adaptation of brain to changes in osmolality. This 
adaptation happens at the expense of loss of intracellular osmolytes, which 
normally protect the brain from a rapid increase in osmolality of the ECF. In these 
patients, sudden increase in plasma osmolality results in water moving out of 
neurons, leading to shrinkage of cerebral tissue. This is the possible reason for  
central  myelinolysis, which was first described in the pons, but can occur diffusely 
throughout the brain.  
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          Neurological deterioration typically occurs over several days with 
fluctuating level of consciousness, seizures, respiratory depression and 
hypotension. Ultimately, patients may present with pseudobulbar palsy with 
dysphagia,  inability to speak and use all four limbs. Recovery from this syndrome 
is variable, and many neurological problems are permanent. The magnetic 
resonance imaging (MRI) imaging demonstrate the demyelinated lesions 3-4 
weeks after the treatment of hyponatraemia. 
        Hyponatraemic encephalopathy is most likely to occur in patients who suffer 
a hypoxic incident  and have underlying severe liver disease, and in premenopausal 
females. As there is no effective treatment after the occurance of central 
demyelination, prevention is of primary mode of treatment. 
      Neurological deterioration typically develops over several days with 
fluctuating consciousness, convulsions, hypoventilation and hypotension. 
Eventually, patients may develop pseudobulbar palsy with difficulty in 
swallowing, inability to speak and quadriparesis. Recovery from this syndrome is 
variable, and many neurological complications are permanent. The magnetic 
resonance imaging (MRI) scans demonstrate the demyelinated lesions 3-4 weeks 
after the correction of hyponatraemia. 
        Neurological deterioration typically develops over several days with 
fluctuating consciousness, convulsions, hypoventilation and hypotension. 
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Eventually, patients may develop pseudobulbar palsy with difficulty in 
swallowing, inability to speak and quadriparesis. Recovery from this syndrome is 
variable, and many neurological complications are permanent. The magnetic 
resonance imaging (MRI) scans demonstrate the demyelinated lesions 3-4 weeks 
after the correction of hyponatraemia. 
TREATMENT OF HYPONATREMIA 
           Therapy for hyponatremia should  be individualized.  Patients with the risk 
of hyponatremia-associated complications should  be balanced against the risk of 
serum sodium correction. Several important factors should be taken before 
deciding  treatment, including the following: 
• The rapidity of onset of hyponatremia 
• The degree, duration, and clinical features of hyponatremia 
• The presence or absence of risk factors for neurologic problems 
ACUTE SYMPTOMATIC HYPONATREMIA 
         Acute symptomatic hyponatremia occurs in less than 48 hours. Clinical 
features are mainly related to cerebral dysfunction resulting from brain cell edema. 
Once the serum sodium concentration falls below 125 mEq/L, neurologic features 
predominate. In acute severe and rapidly developing hyponatremia, the risk of 
complications of cerebral edema more than the risk of osmotic demyelination.  so 
treatment should begin promptly. 
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        Prompt monitoring of correction of the serum sodium concentration is 
indicated for patients with acute severe  symptomatic hyponatremia. The primary 
aim is to increase the serum sodium concentration by 1.5 to 2 mEq/L/hour until  
symptoms decreases.  The main focus being to decrease the risk of seizures. Even 
in symptomatic patients, the sodium concentration should not be increased by more 
than 12 mEq/L in the first 24 hours and by more than 18 mEq/L in the first 48 
hours, in order to avoid central pontine myelinolysis . 
         Infusion of hypertonic fluid (3% Nacl) at a rate of 1 to 2 mL/kg/hour and 
addition of a loop diuretic, to increase the water excretion, are commonly used to 
achieve this aim. Hypertonic fluid may be given at a rate of 4 to 6mL/kg/hour if 
patient presented with severe neurologic symptoms, particularly seizures, are 
present. Once a patient is symptoms free and sodium concentyation are greater 
than 118 mEq/L, correction should be gradualy reduced  to no more than 8 mEq/L 
in 24 hours to attain a target concentration of 125 mEq/L. In all patients, aggresive 
monitoring of serum sodium and electrolytes levels is mandatory until sodium 
levels increase and symptoms subside. 
        A recent alternative management to saline administration in the treatment  of 
hyponatraemia  is the use of ADH receptor antagonists. The most particular  
management  for SIADH is to block the V2 receptors in the renal tubules that 
mediate the diuretic effect of ADH. Vasopressin antagonists are recently indicated  
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for the management of euvolaemic and hypervolaemic hyponatraemia, and these 
agents are commonly used if SIADH or ADH is the cause. 
        Currently, an orally active vasopressin receptor antagonist tolvaptan is 
available. The usefulness of oral tolvaptan in ambulatory patients with SIADH, 
heart failure and cirrhosis is recently demonstrated. V2-receptor antagonist is not 
useful for particular causes of hyponatraemia, such as Cerebral salt wasting 
syndrome, psychogenic polydipsia and beer potomania. 
       While SIADH is commonly  a transient problem, a chronic phase may occur in 
patients with ectopic ADH secreting tumours and in patients is useing 
antipsychotic drugs . If water restriction and salt tablet therapy are not useful in 
these patients, the following drug therapy is useful to antagonise the effect of ADH 
,administration of loop diuretic along with salt tablets; 
• demeclocycline; 
• lithium carbonate;   
• orally active vasopressin antagonists such as tolvaptan. 
        Infusion  of loop diuretic (20 mg furosemide orally twice a day) along with 
salt tablets will  antagonise the effect of ADH but also decreases the oedema 
formation by the latter. 
       Oral Demeclocycline (300-600 mg twice a day ) inhibits the effect of ADH in 
the renal collecting tubule. It requires 7 days to act in renal tubules, and urinary 
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concentrating effect is always impaired, causing in nephrogenic diabetes insipidus 
and even hypernatraemia. Demeclocycline is nephrotoxic drug in patients  having 
cirrhosis and is contraindicated in children because some side effects like bone 
development problems and teeth discoloration. 
      Oral Lithium carbonate (300 mg ,twice a day) also inhibits the action of ADH. 
It is less useful than demeclocycline and when used in long duration, it  can induce 
interstitial nephritis and acure renal failure. So, lithium should be used for  only in 
patients where demeclocycline is contraindicated, such as children and cases with 
liver disorders. 
Treatment options for hyponatremia 
treatment mechanism Limitation 
Fluidrestriction Induces negative water 
balance 
Increases plasma osmolality 
and serum sodium 
 
No direct inhibition of 
excess hormone 
No inhibition of hormone 
on kidney 
nonadherence 
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Treatment mechanism Limitation 
Demeclocycline Impairs AVP action at 
renal tubules 
Induce nephrogenic DI 
Nephrotoxicity (cirrhosis 
patients) Hypersensitivity 
Drug interactions 
 Unsafe in pregnancy 
Urea Decreases sodium 
excretion 
Unsafe in pregnancy 
Azotemia 
Liver failure 
Can reduce effects of 
lithium 
Lithium Impairs AVP at renal 
tubules 
Inconsistent results 
Lithium toxicity 
Anti-anabolic effects  in 
cirrhosis and congestive 
heart failure 
Diuretics 
(loop/thiazide) 
Increase water excretion 
by inhibiting sodium and  
chloride reabsorption in 
loop of Henle and distal 
tubule 
Hypersensitivity 
Hepatic coma 
Anuria 
Severe electrolyte 
depletion 
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COMPLICATION OF TREATMENT 
Central pontine myelinolysis is the important complication after rapid correction 
with sodium. 
 CLINICAL PRESENTATION 
The clinical presentation may be different, may present with a rapidly 
evolving  paraparesis or quadriparesis and pseudobulbar palsy. They may present 
as locked in syndrome, in which intellectual activitys are preserved but cannot be 
expressed. Less often it can present as  ataxia and other movement disorders or 
behavioural symptoms. 
DIAGNOSIS 
Diagnosis  is mainly  based on clinical suspicion and is confirmed by 
imaging . MRI is the primary method for diagnosis and is superior to CT. 
MANAGEMENT 
         The most critical step in the management of CPM is recognizing   the patient 
at risk and preventing  rapid  correction of hyponatremia-especially chronic severe 
hyponatremia. Once a diagnosis is confirmed, the treatment of CPM is usually 
supportive. 
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                                              HEART FAILURE  
DEFINITION 
The current American College of Cardiology Foundation (ACCF)/American 
Heart Association (AHA) guidelines define HF as a complex clinical syndrome 
that results from structural or functional impairment of ventricular filling or 
ejection of blood, which  leads to the chief clinical symptoms of dyspnea and 
fatigue and signs of HF, namely edema and rales 
Some patients present without sign and symptoms. 
The  prevalence of HF is thought to be increasing, in part because current 
recent treatment for cardiac disease , such as acute myocardial infarction (MI), 
structural  
heart disease, and arrhythmias, are allowing patients to survive longer duration 
with variable clinical manifestation. 
HF patients are now broadly classified into HF with a reduced EF (HFrEF; 
previously  known as systolic failure) or HF with a preserved EF (HRpEF; 
previously known as  diastolic failure) . 
          Any condition that leads to an alteration in LV structure or function can 
predispose a patient to developing HF. 
Most common causes of heart failure  are  
      1.coronary heart disease 
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      2.hypertension 
            Both of these condition interact with each other leads to worsening of heart 
faiure. Although the contribution of   diabetes mellitus to HF is not well known, 
diabetes hastens   atherosclerosis   and  often is  associated  with  hypertension. 
In 20–30% of the patients with  HF with a reduced  EF, the exact causes  is not 
known. These patients are referred to as having non ischemic, dilated, or idiopathic 
cardiomyopathy . 
Other causes of heart failure 
  1.viral infection 
  2.toxin exposure like alcohol and chemotheraphy drugs 
  3. Genetic defects in the cytoskeleton like desmin , cardia myocin, virculin and     
laminin in patients with duchenne’s, becker’s , limb girdle muscular dystyophy 
 
PATHOGENESIS 
        Heart failure is the progressive disorder.It is initiated after index event.this 
event may damage the cardiac musculature resulting loss of function and disrups 
the ability to produce adequate force. This index event may be acute like 
myocardial infarction and gradual causes like pressure or volume overload status. 
All causes leads to left ventricular dysfuction. 
                   Some patients with LV dysfunction may remain asymptomatic for 
some duration of illness, one probable explanation is that a number of 
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compensatory mechanisms become triggered in the presence of cardiac injury 
and/or LV dysfunction .These factors allow the patient with symtoms free for 
some duration. 
CAUSES OF HEART FAILURE 
HFrEF HFpEF 
Myocardial infarction/ischemia 
Hypertension 
Obstructive/regurgitant valvular disease 
Intracardiac/extra shunting 
Corpulmonale 
Pulmonary vascular disorder 
Genetic disorder 
Metabolic disorder 
Viral  
Chagas disease 
Bradyarrhythmias 
Tachyarrhythmias 
 
Hypertrophic cardiomyopathy 
Secondary hypertension 
Aging 
Amyloidosis 
Sarcoidosis 
Fibrosis 
Endomyocardial disorder 
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COMPENSATORY MECHANISMS 
• activation of the renin-angiotensin-aldosterone (RAA) and adrenergic nervous 
systems, which are responsible for maintaining cardiac output through increased 
retention of salt and water 
• increased myocardial contractility 
• There is activation of a family of compensating vasodilatory molecules like the 
atrial and brain natriuretic peptides (ANP and BNP), prostaglandins (PGE2 and 
PGI2), and nitric oxide (NO), that offsets the excessive peripheral vascular 
constriction. 
       These factors maintains the patient in asymptomatic status and minimally 
symptomatic. At some point patients become  symptomatic, with a resultant 
striking increase in morbidity and mortality rates. Although the exact mechanisms 
that are responsible for this transition are not known .During transition  period 
,there is increasing activation of neurohormonal, adrenergic and cytokine systems 
that lead to a series of adaptive changes within the myocardium collectively known 
as LV remodeling. 
NEUROHUMORAL ACTIVATION IN HEART FAILURE 
          The decreased cadriac output in HF patient causes unloading of high 
pressure baroreceptor present in the left ventricle , carotid sinus and aortic arch 
receptors , leads to  loss of inhibitory parasympathetic stimuli to the ce nervous 
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system (CNS), with a resultant generalized activation of efferent sympathetic tone, 
and nonosmotic secretion of arginine vasopressin (AVP) from the pituitary. . AVP 
(or antidiuretic hormone [ADH]) is a potent vasoconstrictor that increases the 
permeability of collecting ducts in kidney, leading to the reabsorption of free  
water. Sympathetic nervous system stimulation of  the heart, kidney, peripheral 
vasculature, and skeletal muscles leads to volume overload. 
        Sympathetic stimulation of the kidney leads to the secretion  of renin, with  
increase in the circulating levels of angiotensin II and aldosterone. The activation 
of the renin-angiotensin-aldosterone system encourages salt and water retention 
and leads to vasoconstriction of the peripheral vasculature,   cardiac  
hypertrophy,cardiac cell death, and myocardial fibrosis. These neurohormonal 
mechanisms assist  short-term  alteration by maintaining blood pressure, and hence 
perfusion to important organs, the same neurohormonal mechanisms are supposed 
to contribute to end-organ changes. 
CELLULAR AND MOLECULAR CHANGES 
1. Cardiac myocyte hypertrophy 
2. changes in the contractile properties of the cardiac musculature 
3. gradual loss of myocytes through necrosis, apoptosis, and autophagic cell 
death 
4. β-adrenergic desensitization; 
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5. changes  myocardial energetics and metabolism; 
restructuring of the extracellular matrix with disbanding of the organized structural 
collagen, followed by replacement of structural collagen by non structural 
interstitial collagen which not give support to the muscularure 
.BIOLOGIC STIMULI FOR CELLULAR CHANGES  
1. mechanical stretch of the cardiac myocyte  
2. circulating neurohormones (e.g., noradrenaline, angiotensin II), 
3. inflammatory markers (e.g., tumor necrosis factor [TNF]),  
4. peptides and growth factors (e.g., endothelin), and 
5. reactive oxygen species (e.g., superoxide). 
         Continuous neurohormonal activation and mechanical overload cause in 
transcriptional and posttranscriptional modification in the genes and proteins that 
control excitation-contraction coupling and cross-bridge interaction.   
 The changes  in the excitation-contraction are 
 1.decreased  function of sarcoplasmic reticulum Ca2+ adenosine 
triphosphatase (SERCA2A), causing   decreased calcium uptake into the 
sarcoplasmic reticulum   
2. hyperphosphorylation of the ryanodine receptor, causing  calcium leakage 
from the SR.  
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The changes  occur in the cross-bridges are 
1. decreased appearance of α-myosin heavy chain 
 2. increased appearance of β-myosin heavy chain, 
 3.myocytolysis, and disturbance of the cytoskeletal links between the 
sarcomeres and the extracellular matrix. 
All these modification impairs the ability of the cardiac myocyte to contract 
normaly and therefore contribute to the reduced left ventricular systolic function 
noted in patients with HF. 
ATP is the important molecule for myocardial relaxation.during myocardial 
ischemia consentration of ATP is decreased , leads to impairment in relaxation and 
increased stiffness secondary to hypertrophy. In addition to distrubed myocardial 
relaxation, increased myocardial stiffness  and increased myocardial nonstructural 
collagen content may contribute to diastolic failure. Importantly, diastolic failure 
can occur alone or in combined with systolic failure in patients with HF. 
LEFT VENTRICULAR REMODELING 
It is refered as  changes in Left Ventricular  mass, volume, and  shape and 
the composition of the heart that occur after index event  and/or abnormal 
hemodynamic changes. LV remodeling  independently leads to progression of  
 
34 
 
heart failure.left ventricular wall became thin and get dilated due to    increased LV 
end diastolic volume.  
High end diastolic stress cause 
(1) .hypoperfusion of subendocardium causing worsening of failure 
(2) increased oxidative stress with activation of  genes that are sensitive to 
free radical generation (e.g., TNF and interleukin 1β) leads to myocardial injury 
(3) continuous activation of stretch-activated genes (angiotensin II, 
endothelin, and TNF) and stretch activation of hypertrophic signaling pathways. 
CLINICAL FEATURES 
The main  symptoms of HF are fatigue and  breathlessness. Fatigue is due to 
the low cardiac output in patient  HF,  skeletal-muscle abnormalities and other 
noncardiac condition like  anemia . In the early stages of HF, breathlesness is 
witnessed  only during exercise; once disease progresses, dyspnea occurs with less 
vigorous activity, and it  may occur even at rest. The causes of dyspnea in HF is 
multifactorial. The most principal  mechanism is congestion of pulmonary 
vascylature with accumulation of in the  interstitial or intra-alveolar space, which 
stimulates juxtacapillary J receptors, which in turn stimulate the rapid, shallow 
breathing . Other causes of  dyspnea on exertion are decreased pulmonary 
compliance, increased  resistance in airways  , fatiquability of  respiratory muscle   
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and/or diaphragm and anemia. Dyspnea become less when  right ventricular (RV) 
failure and tricuspid regurgitation develops. 
          Orthopnea is defined as dyspnea occurring in the recumbent posture, is 
commonly a later symptoms of HF . It occurs due to redistribution of fluid from 
the splanchnic circulation and lower extremities into the central circulation during 
recumbent posture, which leads to increase in pulmonary capillary pressure. 
          Nocturnal cough is most common clinical manifestation of this process. 
Orthopnea usually is relieved by sitting upright posture or sleeping with extra 
pillows. Orthopnea is a relatively specific feature of HF, it may also occur in 
patients  ascites  and  pulmonary disease . 
PAROXYSMAL NOCTURNAL DYSPNEA (PND)  refered as acute 
episodes of severe  dyspnea and coughing that  occur at night and awaken the 
patient from sleep, usually 1–3 h after the  patient retires. PND may present as 
coughing or wheezing, possibly  due to increased  bronchial arteries pressure 
leading to compression in the airways, along with interstitial pulmonary edema that 
leads to increased  resistance in the airways. Cardiac asthma is commonly related 
to PND, is characterized by wheezing secondary to bronchospasm, and must be 
differentiated from primary pulmonary causes of wheezing. 
CHEYNE-STOKES RESPIRATION Also known as periodic  or  cyclic 
respiration, It is present in 35%-40% of patients with severe HF and commonly 
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associated with low cardiac output. It  occurs due to increased sensitivity of the 
respiratory center to arterial PCO2. It is characterised by apneic phase, during 
which arterial PO2 decreases and arterial PCO2 increases. These modification in 
the arterial blood gas   stimulate  respiratory center in the brain resulting in 
hyperventilation and hypocapnia, followed by recurrent apnea.  
It may present as acute pulmonary edema. 
Other clinical features HF are present with anorexia, nausea, and early 
satiety  with abdominal pain and fullness . It  may be due to edema of the bowel 
wall and a congestion of liver. Congested  liver and stretching of its capsule may 
lead to right upper-quadrant pain. Cerebral features like confusion, disorientation, 
and sleep and mood disturbances are observed in patients with advanced HF, 
usually elderly patients with cerebral arteriosclerosis and decreased cerebral 
perfusion. Nocturia is common clinical feature  of HF and may leads to insomnia. 
PHYSICAL EXAMINATION 
 In mild to  moderately severe HF, the patient feels no distress at rest except  
uncomfortable when lying on supine position  for more than a few minutes. In 
advanced  HF, the patient must sit in upright posture, may have labored breathing, 
and may not be able to complete a sentence because of  dyepnea. Systolic blood 
pressure may be normal or high in early stage of  HF, but it usually is reduced in 
late stage of HF because of severe LV systolic dysfunction. The pulse pressure is 
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diminished, reflecting reduced  in stroke volume. Sinus tachycardia is a commom 
clinical finding. It is a  nonspecific sign caused by increased adrenergic activity 
which leads toPeripheral vasoconstriction(cool peripheral extremities) and 
cyanosis of the lips and nail beds. 
          In the mild stages of HF, the jugular  venous pressure may be normal at rest 
but  positive abdominojugular reflux is present. Giant v waves is usually seen in  
tricuspid regurgitation. 
PULMONARY EXAMINATION 
 Pulmonary crackles ( crepitations) usually due to transudation of fluid from 
the intravascular space to the alveolar space. In  pulmonary edema, patient present 
with rales  over both lung fields and  expiratory wheezing . Rales are specific when 
it is present without lung disease. Rales are commonly absent in patients with 
chronic HF because of adequate lymphatic drainage of alveolar fluid.  Pleural 
effusions occur usually with biventricular failure. Pleural effusion is often bilateral 
in HF, when they are unilateral, they occur commonly in the right pleural space. 
CARDIAC EXAMINATION 
1.apical impulse shifted to downwards and lateraly due to cadiomegaly 
2. Third heart sound (S3)is palpable and audible 
3.tachycardia and tachypenea 
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4,Fourth heart sound(S4) is not a specific indicator of HF but is commonly 
present in patients with diastolic LV dysfunction. The  mitral and tricuspid 
regurgitation murmurs are often present in patients with severe HF. 
ABDOMINAL EXAMINATION 
Tender hepatomegaly , pulsate liver (  if tricuspid regurgitation) are  present. 
Ascites and jaundice are usually  late clinical finding in advanced  HF.Both direct 
and indirect bilirubin are elevated.Peripheral edema is a common  manifestation of 
HF, but it is nonspecific and usually  not present in patients who are treated  with 
diuretics. Peripheral edema is always symmetric and dependent in HF and presen 
in  ankles and the pretibial region in ambulatory cases. In bedridden patients, 
edema is found in the sacral area  and the scrotum. Long-standing edema leads to 
induration and pigmentation of skin. 
 CARDIAC CACHEXIA 
 With severe  advanced  HF, patient present with weight loss and cachexia. It 
is probably due to multifactorial and includes elevation of the resting metabolic 
rate; anorexia, nausea, and vomiting due to congestion of liver and abdominal 
fullness; elevation of circulating levels cytokines like TNF; and decreased 
intestinal absorption is due to congestion of veins present in  the intestinal wall.  
When present, it indicate  poor  prognosis. 
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INVESTIGATION 
 complete blood count 
 a panel of electrolytes 
 blood urea nitrogen 
 serum creatinine hepatic enzymes 
 urinalysis. 
 Selected patients need  fasting serum glucose(DM)  
 fasting lipid panel (dyslipidemia) 
 thyroid function test 
 ECG ( to assess rhythm disturbance  LV hypertrophy and prior MI )  
 chest x-raye  
 Two-dimensional (2-D) echocardiogram/ Doppler/EF% 
 B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-
proBNP) 
HF  should be differentiated from (1) disease causing circulatory congestion 
due to salt and water retention(e.g., renal failure), and (2) noncardiac causes of 
pulmonary edema (e.g., acute respiratory distress syndrome). 
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HYPONATREMIA AND ACUTE DECOMPENSATED HEART FAILURE 
 
           Like most other causes of  hyponatremia,HF impairs the ability to excrete 
ingested water by increasing antidiuretic hormone levels.when cardiac output and 
SBP are reduced,hypovolemic hormones, such as renin,ADH and norepinephrine 
respond. Although edematous cases with HF have increased plasma and 
extracellular fluid volume, the body perceives volume depletion since the low CO 
decreases the pressure perfusing the baroreceptors in the carotid sinus and renal 
afferent arteriole. 
The degree of neurohumoral activation is generally related to the severity of 
cardiac dysfunction,as assessed by left ventricular EF of functional class. The 
neurohumoral changes limit both sodium and water excretion in an attempt to 
return perfusion pressure to normal. ADH release directly enhances water 
reabsorption in the collecting tubules whereas angiotensin II and norepinephrine 
limit distal water delivery by lowering the glomerular filtration rate and by 
increasing proximal sodium and water reabsorption.In addition, both the low CO 
and high angiotensin II level are stimuli to thirst, leading to enhanced water intake. 
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                              CARDIORENAL SYNDROME 
 
 
Cardiorenal Syndrome (CRS)  Definition: 
A pathophysiologic disorder of the heart and kidneys whereby acute or chronic 
dysfunction in one organ may induce acute or chronic dysfunction in the other 
organ 
CRS Type I (Acute Cardiorenal Syndrome): 
Abrupt worsening of cardiac function (e.g., acute cardiogenic shock or 
decompensated congestive heart failure) leading to acute kidney injury 
CRS Type II (Chronic Cardiorenal Syndrome): 
Chronic abnormalities in cardiac function (e.g., chronic congestive heart failure) 
causing progressive and permanent chronic kidney disease 
CRS Type III (Acute Renocardiac Syndrome): 
Abrupt worsening of renal function (e.g., acute kidney ischemia or 
glomerulonephritis) causing acute cardiac disorder (e.g., heart failure, arrhythmia, 
ischemia) 
CRS Type IV (Chronic Renocardiac Syndrome): 
Chronic kidney disease (e.g., chronic glomerular disease) contributing to decreased 
cardiac function, cardiac hypertrophy, and/or increased risk of adverse 
cardiovascular events 
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CRS Type V (Secondary Cardiorenal Syndrome): 
Systemic condition (e.g., diabetes mellitus, sepsis) causing both cardiac and renal 
dysfunction 
TYPE 1 CARDIORENAL SYNDROME 
          Type 1 CRS (acute CRS) occurs in approximately 25% to 33% of patients 
admitted with ADHF. There are direct and indirect effects of HF that can be 
identified as the primers for AKI and dysfunction. Factors beyond the classic 
hemodynamic mechanisms appear to play a role in the pathogenesis of renal injury. 
Venous congestion, sympathetic nervous system dysfunction, anemia, activation of 
the renin-angiotensin aldosterone system (RAAS), disruption of the hypothalamic-
pituitary axis, and a marked alteration of immune and somatic cell signaling have 
all been implicated. The complexity of this syndrome presents a key challenge for 
singular diagnostic or treatment approaches.  
there are 4 subtypes of type 1 CRS:  
1) de novo cardiac injury leads to de novo kidney injury;  
2) de novo cardiac injury leads to acute-on-chronic kidney injury;  
3) acute-on-chronic cardiac decompensation leads to de novo kidney injury; and  
4) acute-on-chronic cardiac decompensation leads to acute-on-chronic kidney 
injury. 
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          Type 1 CRS is characterized by an acute heart disorder leading to AKI and 
occurs in ∼25% of  patients admitted with ADHF . Among these patients, pre-
morbid chronic kidney disease (CKD) is common and predisposes to AKI in nearly 
60% of cases. AKI is an independent risk factor for 1-year mortality in ADHF 
patients, including patients with  myocardial infarction who develop  HF or have a 
reduced left ventricular EF . This independent effect might be due to an associated 
acceleration in cardiovascular pathobiology due to kidney dysfunction through the 
activation of neurohormonal, cell signaling, oxidative stress, or exuberant repair 
(fibrosis) pathways.  
Upon initial recognition, AKI induced by primary cardiac impairment    
implies inadequate renal perfusion until proven otherwise . This should prompt 
clinicians to consider the diagnosis of a low CO  state and/or marked increase in 
venous pressure leading to kidney congestion. It is important to remember that 
central venous pressure transmitted to the renal veins is a product of right heart 
function, blood volume, and venous capacitance, which is largely regulated by 
neurohormonal systems.  
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PREDISPOSITION FOR CARDIORENAL SYNDROMES 
 
Obesity and cardiometabolic changes 
        Obesity leads to type 2 diabetes mellitus (DM), hypertension, obstructive 
sleep apnea, atrial fibrillation, HF, hyperuricemia, and CKD, all directly or 
indirectly related to excess adiposity.  The adipocytes secrete cytokines which 
cause cardiac and renal injury by   (IL)-6 and TNF alpha. The  IL-6  release high-
sensitivity C-reactive protein. Thus, hs CRP   levels are increased in obese 
individuals .Changes in the leve lof  lipid content within cardiomyocytes  are 
playing a pathological role in cardiac remodeling. Obesity-related glomerulopathy 
is described as a condition of hyperfiltration in obese individuals without DM that 
ultimately  predisposes to CRS type 1 .cardiometabolic syndrome in the absence of  
DM has been associated with 3- to 7-fold increased risk of CRS type 1 
Cachexia 
        Cachexia and nutritional deficiencies associated with either HF or CKD may 
contribute to further damage and fibrosis of the other organ  and leads to infection 
or death. 
Hypertension and diabetes 
        Hypertension directly related to augmented loss of nephrons and reductions in 
GFR. Diabetes leads to glomerular dysfunction, damage, and ultimate loss of 
function and contributes to kidney failure. 
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Proteinuria 
       Albuminuria and gross proteinuria are associated with the risk of AKI . 
Albuminuria  is predictive of the development of HF. In established HF, 
microalbuminuria is a risk marker for cardiovascular disease. 
Uremic solute retention 
      Uremia causes myocyte dysfunction manifested by impaired movement of 
calcium in the cytosol leads  to impaired contraction of myocyte elements. Uremia 
directly contributes to accelerated fibrosis and adverse cardiac remodeling after 
MI. 
Anemia 
       Anemia in HF is multifactorial, encompassing hemodilution due to water 
retention, blockade of normal iron transport, inflammation/cytokine-induced 
erythropoietin deficiency, and tissue resistance, malnutrition, cachexia, vitamin 
deficiency, all amplified in the presence of pre-existing CKD . 
Repeated episodes of subclinical AKI 
       some individuals undergo repeated episodes of either subclinical or 
unrecognized episodes of AKI over the course of a lifetime develop CRS in the 
setting of ADHF. 
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Cardiac and Renal Fibrosis 
        Increased stress or injury to the myocardium, glomeruli, and renal tubular 
cells, due to uncontrolled hypertension, DM  can involve recruitment of immune 
cells, production of cell signaling proteins from local pericytes, mast cells, and 
macrophages, resulting in activation of resident fibroblasts and myofibroblasts, and 
in the final common pathway, the deposition of procollagen into the extracellular 
matrix, which is irreversibly crosslinked to collagen-generating cardiac and renal 
fibrosis .In the myocardium and the kidney, angiotensin II and aldosterone are 
major stimuli for macrophages to secrete galectin-3, which in turn works as a 
paracrine signal on fibroblasts to help translate the signal of transforming growth 
factor β (T GFβ) to increase cell cycle (cyclin D1) and direct both the proliferation 
of pericytes and fibroblasts, and the deposition of procollagen 1 leads to 
progression of CKD and HF  
The Acute Pathways of CRS Type 1 
Hemodynamics and congestion 
         The increase in blood pressure is likely a reflection of sodium retention and 
sympathetic activation. A dysfunctioning left ventricle is particularly sensitive to    
afterload variations, and therefore, an increase in blood pressure can abruptly 
worsen left ventricular filling pressures, leading to pulmonary congestion 
irrespective of total intravascular volume. Subsequently, a vicious cycle arises in 
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which cardiac remodeling leads to functional mitral regurgitation, further increase 
in left atrial pressure, and pulmonary hypertension. Chronic passive congestion of 
the kidneys results in attenuated vascular reflexes over time. As with the heart, 
venous congestion is one of the most important hemodynamic determinants of 
CRS and has been associated with the development of renal dysfunction in the 
setting of ADHF . It is commonly observed that coexisting renal dysfunction may 
complicate the treatment course of HF and that the use of intravenous loop 
diuretics often alleviate congestion at the cost of worsening renal function within 
days of hospitalization and is a strong, independent predictor of adverse outcomes . 
Although loop diuretics provide prompt diuresis and relief of congestive 
symptoms, they provoke a marked activation of the sympathetic and RAAS, 
resulting in renovascular reflexes and sodium retention, and thus are considered a 
primary precipitant of CRS.  
Volume and Blood Pressure Management Window 
         Patients at risk for cardiorenal syndrome type 1 have a narrow window for 
management of both blood pressure and volume; extremes in either parameter can 
be associated with worsened renal function. 
Neurohormonal activation 
       The RAAS has an important role in the initiation and maintenance of vascular, 
myocardial, and renal dysfunction leading to edema in HF (55). Increased renin 
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secretion occurs early in biventricular failure, which leads to stimulation of 
angiotensin II. Angiotensin II has direct trophic effects on cardiomyocytes and 
renal tubular cells that promotes cellular hypertrophy, apoptosis, and fibrosis .In 
normal subjects, an “escape” from renal salt-retaining effects of aldosterone 
usually occurs after 3 days, thus avoiding edema formation. This aldosterone 
escape phenomenon, however, does not occur in HF patients, and the continued 
sodium retention contributes to the pulmonary congestion and edema, .Aldosterone 
stimulates macrophages in heart and kidney tissue to secrete galectin-3, which in 
turn stimulates fibroblasts to secrete procollagen I and III that is crosslinked to 
collagen, resulting in fibrosis. As a result of sympathetic activation, 
catecholamines play a vital role in the pathogenesis and progression of HF . It is 
well known that elevated plasma norepinephrine levels in patients with HF 
correlate with increased mortality 
Hypothalamic-pituitary stress reaction 
        Activation of corticotrophin releasing factor neurons in the paraventricular 
nucleus of the hypothalamus is necessary for establishing the classic endocrine 
response to stress for example, ADHF. Any stressor that activates the 
hypothalamus-pituitary-adrenal axis leads to an increase in concentrations of the 
adrenal stress hormone cortisol and arginine vasopressin. Arginine vasopressin 
stimulates the V1a receptors of the vasculature and increases systemic vascular 
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resistance, while stimulation of the V2 receptors in the principal cells of the 
collecting duct increases water reabsorption and leads to hyponatremia. Arginine 
vasopressin also enhances urea transport in collecting ducts of the nephron, thereby 
increasing the serum blood urea nitrogen. The clinical consequences of these 
changes include sodium and water retention, pulmonary congestion, and 
hyponatremia, which occurs both in low-output and high-output cardiac failure. It 
is important to recognize that hyponatremia is a relatively late sign of arginine 
vasopressin overstimulation, and thus, earlier modulation of this system is an 
important consideration in treatment. The arterial underfilling occurs secondary to 
a decrease in cardiac output in low-output HF and arterial vasodilatation in high-
output HF, both of which decrease the inhibitory effect of the arterial stretch 
baroreceptors on the sympathetic and RAAS. Thus, a vicious cycle of worsening 
HF and edema formation occurs. 
Inflammation and immune cell signaling 
         Inflammation classically has 4 components: 1) cells; 2) cytokines; 3) 
antibodies; and 4) complement. Thus, the term inflammation in CRS has been 
termed “low-grade” or better described as an imbalance between the immune 
system cell signaling pathways promoting and inhibiting inflammation. Over the 
past 30 years, there has been increasing evidence on the role of activation of the 
inflammatory response in the pathogenesis of different types of heart disease, 
50 
 
including HF. An early work of Levine et al. (63) showed that in patients with 
severe HF, circulating levels of tumor necrosis factor-alpha were much higher than 
normal. Numerous studies showed activation of inflammation at various levels in 
HF patients. Further support for the inflammatory etiology of HF came from the 
demonstration that inflammatory cytokines may also be produced by 
cardiomyocytes, following ischemic or mechanical stimuli, but also by the innate 
immune response, represented by Toll-like receptors, pentraxin-like C-reactive 
protein, and pentraxin 3 (64–69). These findings suggest that in HF, an immune 
dysregulation may exist; cytokines not only could produce distant organ damage 
such as AKI, but they also may play a role in further damaging myocytes. There is 
evidence supporting the prognostic value of various circulating markers of 
inflammation, particularly C-reactive protein, pentraxin 3, tumor necrosis factor-
alpha, IL-1, and IL-6. 
         Excessive elevations of cytokines and markers of inflammation have been 
consistently documented in ADHF (75). Inflammatory activation may have a role 
in HF by contributing to both vascular dysfunction and fluid overload in the 
extravascular space (76). The amount of fluid in the pulmonary interstitium and 
alveoli is tightly controlled by an active process of reabsorption. Recent studies 
have shown that inflammation interferes with this process and thus leads to 
pulmonary fluid overload despite no increase in total body fluid (77,78). This 
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mechanism could be a cause for inadequate renal perfusion pressures, peritubular 
edema, pathological reduction of glomerular filtration, and finally, mixed 
inflammatory and ischemic tubular damage. 
The role of the gut and endotoxemia 
       Underperfusion of the intestine and the hematogenous release of endotoxin in 
patients with HF has been proposed as a mechanism for progression of HF and 
CRS type 1, particularly in patients with cachexia  
Superimposed infection 
        Superimposed infection, often pneumonia, is a common precipitating or 
complicating factor in ADHF. 
Iatrogenesis 
            Among the mechanisms involved in organ crosstalk between the heart and 
kidney, we must consider iatrogenesis. In several clinical conditions, drugs 
required to treat DM, oncological diseases, infections, HF itself, or fluid overload 
may affect the delicate balance between the heart and the kidney, leading to 
progressive deterioration of both. Metformin is an antidiabetic drug that can result 
in lactic acid accumulation and worsening heart function due to a negative 
inotropic effect. Chemotherapeutic agents used in solid tumor treatments may 
induce a tumor lysis syndrome, with a sudden increase in circulating uric acid 
levels. Such an effect, although less dramatic, may also be induced by diuretic 
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therapy. Uric acid, as discussed in the preceding text, is potentially toxic to the 
myocardium as well as for the tubulointerstitial component of the kidney. 
Antibiotics may cause interstitial nephritis and tubular dysfunction, and 
contribution to progressive renal insufficiency, especially when glomerular 
filtration is stressed by a low cardiac output and activation of the RAAS . Iodinated 
contrast causes a much different form of AKI characterized by transient 
vasoconstriction and decreased perfusion followed by direct tubular toxicity as the 
contrast is taken up by proximal tubular cells and transported into the interstitium 
in the kidney. Contrast-induced nephropathy can be an important cause of negative 
feedback on the heart with progressive worsening of cardiac disease due to uremic 
complications . Cardiac surgery is a well-recognized antecedent to type 1 CRS and 
AKI, particularly if the patient has received contrast in the days before the 
operation. Because this is one of the timed forms of AKI, there has been 
considerable effort in demonstrating the novel markers of AKI (neutrophil 
gelatinase-associated lipocalin, kidney injury molecule [KIM]-1, L-type fatty acid 
binding protein [LFABP], N-acetyl-β-D-glucosaminidase [NAG], and others) serve 
as both baseline risk predictors and diagnostic indicators of kidney damage after 
cardiac surgery . 
          Progressive salt and water retention alter intraglomerular hemodynamics and 
thereby influence physiological tubular-glomerular feedback . Patients may already 
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be undergoing treatment with angiotensin-converting enzyme inhibitors, 
angiotensin II receptor blockers, direct renin inhibitors, and/or aldosterone 
blockers, all of which may negatively impact tubuloglomerular feedback. 
However, holding these agents, while temporarily causing less creatinine retention 
in the blood pool, has been associated with worsening of HF over the longer term. 
Combinations of angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers, direct renin inhibitors, and especially aldosterone blockers when 
glomerular filtration rate is reduced below 45 ml/min, may lead to secondary 
hyperkalemia. Nonsteroidal inflammatory agents reversibly inhibit 
cyclooxygenases 1 and 2, impair prostaglandin synthesis, and result in sodium and 
fluid retention, as well as tissue edema, which consistently worsen HF outcomes . 
In the kidney, edema may result in impaired oxygenation and metabolite diffusion, 
distorted tissue architecture, obstruction of capillary blood flow and lymphatic 
drainage, and disturbed cell–cell interactions that may then contribute to 
progressive organ dysfunction. 
         The cornerstone of treatment for ADHF is the use of oral and intravenous 
loop diuretics. These agents represent a double-edged sword as they may resolve 
congestion but worsen renal perfusion by arterial underfilling and heightened 
activation of the sympathetic and RAAS leading to type 1 CRS . 
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         Although registry data have demonstrated that earlier diuretic use decreases 
mortality in severe ADHF, there is an overall relationship between increased loop 
diuretic dosing and mortality Felker et al. , in a small randomized trial of ADHF, 
demonstrated that higher doses and continuous infusions of furosemide resulted in 
more patients developing AKI (rise in creatine >0.3 mg/dl) with no improvement 
in hospitalization or death. These arguments suggest the clinician needs better 
guidance on the use of loop diuretics in ADHF. Two such sources of guidance 
include the use of bioimpedance to estimate body water levels as well as novel 
biomarkers of AKI such as neutrophil gelatinase-associated lipocalin, which rises 
in the setting of diuretic-induced AKI . 
 
Oxidative Stress: Final Common Pathway of Injury 
Oxidative stress is a final common pathway for cellular dysfunction, tissue injury, 
and organ failure. The most widely recognized chemical reactions generating 
reactive oxygen species are the Haber-Weiss and Fenton equations. These 
equations require oxygen, water, hydrogen, and a metal catalyst in the form of iron, 
copper, and so on. Since iron is the most abundant metal element in cells, it is 
believed that labile iron is the major stimulus for oxidative stress that results in 
tissue injury . The release of poorly liganded labile iron that remains unbound in a 
fraction has been implicated in both acute ischemic cardiac models and a variety of 
injury models in the kidney. Importantly, labile iron transitioning from Fe2+ to 
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Fe3+ facilitates the production of hydrogen peroxide and the dangerous hydroxyl 
radical, which overwhelm the homeostatic antioxidant defense mechanisms in cells 
. Attempts to slow these reactions may have benefit, particularly for the kidney, 
and include alkalinization, cooling, and binding the iron catalyst. It is important to 
recognize in probably every case of CRS that oxidative stress and injury to both 
the heart and kidneys is playing a potentially reversible role and that these 
mechanisms represent a final common pathway for tissue damage and organ 
failure. 
Failure of Counter-Regulatory Mechanisms 
 In response to wall tension, the cardiomyocyte produces large quantities of 
natriuretic peptides that work to reduce wall tension, vasodilate, and promote 
natriuresis and diuresis .Ischemia is also recognized as a stimulus for natriuretic 
peptide production. Natriuretic peptides, working via natriuretic peptide receptors 
in the glomerulus and the renal tubules, activate cCMP and reduce sodium 
reabsorption. When given in supraphysiological doses, B-type natriuretic peptide 
reduces levels of catecholamines, angiotensin II, and aldosterone . However, this 
counter-regulatory set of functions appears to be overwhelmed in CRS type 1, and 
thus, the patient worsens clinically and develops oliguria in the setting of markedly 
elevated levels of natriuretic peptides.  
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MATERIALS AND METHODS : 
 
STUDY POPULATION: 
source of data: 
The study will be conducted on 100 patients admitted to Government Rajaji 
Hospital & Madurai Medical College during the study period from april  2017 to 
september  2017. 
Inclusion criteria: 
        All patients with acute decompenstated heart failure of any etiology with a 
duration of hospital stay more than 24 hours with or without renal dysfunction 
Exclusion criteria: 
1.Patients with documented renal artery stenosis 
2.Patient with diabetic nephropathy(proteinuria >300mg.24 hours 
3.Patients with chronic kidney disease (Sr.creatinine >5mg/dl) 
4.Patients with history of NSAID abuse 
5.Patients not satisfying above criteria(hospital stay <24 hours) 
ANTICIPATED OUTCOME: 
       Hyponatremia as an independent risk factor for acute decompenstated heart 
failure and important factor contributing to the development of WRF  . 
 
 
57 
 
DATA COLLECTION: 
      Informed consent will be obtained from all patients to be enrolled for the study. 
In all the patients relevant information will be collected in a predesigned proforma. 
       The patients are selected based on clinical examinations, biochemical tests and 
echocardiogram. The patients are followed over a period of six months with serum 
sodium and creatinine levels measured at regular intervals. 
LABORATORY INVESTIGATIONS 
a)Complete blood count, 
b)Renal function test, 
c)Urine routine, 
d)Serum electrolyte, 
e)Electrocardiogram, 
f)Echo 
g)USG abdomen 
 
STUDY PROTOCOL 
• Patients with clinical and radiological evidence of   acute decompensated 
heart failure  are to be   included in the study. 
• Then they are classified  into structural, ischemic and electrical 
abnormalities by clinical , radiological and biochemical evaluation  
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• In all the patients above investigation are done to classify them as mild 
hyponatremia , moderate hyponatremia and severe hyponatremia 
• Above patients are further classified as having worsening renal function by 
correlating with creatinine  levels  
 
DESIGN OF STUDY: 
 Prospective study. 
PERIOD OF STUDY: 
6 MONTHS (april 2017 to September 2017) 
COLLABORATING DEPARTMENTS: 
         DEPARTMENT OF CARDIOLOGY 
         DEPARTMENT OF NEPHROLOGY 
         DEPARTMENT OF BIOCHEMISTRY 
 
CONSENT: Individual written and informed consent. 
ANALYSIS: Statistical analysis will be performed using appropriate tests as 
required according to data. 
CONFLICT OF INTEREST: NIL 
PARTICIPANTS:  
      100  acute decompensated heart failure at Government Rajaji hospital, Madurai  
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METHOD OF STUDY 
       This study was conducted in Govt. Rajaji Hospital, Madurai which is allied  to 
Madurai Medical College. This study subjects were choosen from the patients 
admitted in Department of Medicine and Department of cardiology , Govt. Rajaji 
Hospital madurai. 
      The study was conducted in 100 patients with acute decompensated heart 
failure of any cause without chronic renal failure with clinical background of  
diabetes mellitus ,hypertension ,coronary artery disease , valvular heart disease and 
arrthythmia. 
Clinical criteria to classify patients having acute decompensated heart failure 
worsening renal function 
        If the patient had oedema legs, ascites, cardiac enlargement, radiological 
evidence of congested lungs and responded to treatment for congestive cardiac 
failure , then the diagnosis of congestive cardiac failure was made. 
 
      When there were raised serum urea and creatinine levels when compared with  
previous levels along with signs and symptoms  with excluding  chronic kidney 
disease . 
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Classification Hyponatremia(mEq/l) Worsening renal 
function(mg/dl) 
Mild 130-135 1.2- 2 
Moderate 125-129 2-3 
Severe Less than 125  More than 4 
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RESULTS AND INTERPRETATION 
GENDER DISTRIBUTION 
 
 
GENDER frequency Valid persent 
female 40 40 
male 60 60 
total 100 100 
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                                               AGE DISTRIBUTION 
 
 
Age group frequency  
<40 16 16 
40-60 62 62 
>60 22 22 
total 100 100 
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                         DISTRIBUTION OF ANEMIA 
 
 
 
 
anemia frequency Valid persent 
absent 68 68 
present 32 32 
total 100 100 
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DISTRIBUTION OF DRUG USAGE 
 
 
 
medication frequency Valid percent 
absent 46 46 
present 54 54 
total 100 100 
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DISTRIBUTION OF DM 
 
 
 
Diabetes mellitus frequency Valid persent 
absent 40 40 
present 60 60 
total 100 100 
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DISTRIBUTION OF HYPERTENSION 
 
 
 
hypertension frequency Valid percent 
Absent 49 49 
present 51 51 
total 100 100 
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DISTRIBUTION OF CAD 
 
 
 
 
cad frequency Valid persent 
absent 45 45 
present 55 55 
total 100 100 
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DISTRIBUTION OF DCM 
 
 
 
DCM frequency Valid present 
absent 75 75 
present 25 25 
total 100 100 
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DISTRIBUTION OF MYOCARDITIS 
 
 
myocarditis frequency Valid percent 
absent 96 96 
present 04 04 
total 100 100 
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DISTRIBUTION OF ARRHYTHMIA 
 
 
 
arrthythmia frequency Valid percent 
absent 80 80 
Present 20 20 
total 100 100 
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WEIGHT DISTRIBUTION AMONG MALES 
Weight(male) frequency Valid persent 
<60 25 41.66 
>60 35 58.33 
total 60 100 
 
WEIGHT DISTRIBUTION AMONG FEMALES 
Weight(female) frequency Valid persent 
<55 16 40 
>55 24 60 
total 40 100 
 
DISTRIBUTION OF HEART DISEASE 
Valvular disease frequency Valid persent 
absent 86 86 
present 14 14 
total 100 100 
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CORRELATION BETWEEN SODIUM AND CREATININE LEVELS ON 
ADMISSION 
 
Na mEq/l freq Valid % ON Cr mg% freq Valid % 
130-135 30 30 ADMIS <2 1 1 
125-129 34 34 SION 2-3 60 60 
<125 36 36  >3 39 39 
Total 100 100  total 100 100 
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CORRELATION BETWEEN SODIUM AND CREATININE LEVELS 
AFTER THREE MONTHS 
 
Na mEq/l freq Valid % After 3 Cr mg% freq Valid% 
130-135 36 36 Months <2 04 04 
125-129 42 42  2-3 81 81 
<125 22 22  >3 15 15 
Total 100 100   100 100 
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CORRELATION BETWEEN SODIUM AND CREATININE LEVELS 
AFTER SIX MONTHS 
 
 
Na mEg/l freq Vaild% At 6 Cr mg/dl freq Valid% 
130-135 100 100 months 100 100 100 
125-129 0 0  0 0 0 
<125 0 0  0 0 0 
Total 100 100  100 100 100 
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STATISTICAL CORRELATION BETWEEN SODIUM AND CREATININE 
 
period Mean Std 
deviation 
correlation 
value(r value) 
Pearson 
correlation 
test p value
Admission na 125.68 4.900794 -0.583 Negative 
correlation 
0.0001 
Cr 2.875 0.46349 
At 3 
month 
Na 127.24 4.1854 -0.34 Negative 
correlation 
0.001 
Cr 2.683 0.387704 
At 6 
months 
Na 138.14 2.778053 -0.301 Negative 
correlation 
0.002 
Cr 1.109 0.241667 
  significant p value 
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DISCUSSION 
This study was undertaken keeping in view of frequent occurrence of 
htponatremia in acute decompensated heart failure patient who are at highest risk 
of developing electrolyte disturbance and acute renal failure. 
In the present study totally 100 patients are included. Out of  100 patients 
,40% (40) were female, 60%(60) were male. 
In this study, 16%(16) of patients were presented below 40 years, 62% 
(62)patients between 40-60 years and 22% (22) patients above 60 years. 
In the present study,32% had anemia,54% had history of drug intake,60% 
had diabetes mellitus,51% had hypertension,55% had coronary artery disease,25% 
had dilated cardiomyopathy,4% had myocarditis, 14% had valvular heart disease 
and 20% had arrhythmia. 
Some patients had more than one risk factors.hypertension,diabetes mellitus, 
drug intake and anemia are the most important risk factors associated with acute 
decompensated heart failure. 
At the time of admission in hospital, patient with ADHF had different levels 
of sodium concentration and  different serum creatinine level.  patient with severe 
hyponatremia  had more serum creatinine when compared with moderate and mild 
hyponatremia.  
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         After three months of treatment, some patient became severe hyponatremia 
with more serum creatinine  and some patiend had corrected sodium levels winh 
minimal cretinine changes. After six months ,maximum number of patient had 
acceptable variation in serum sodium and creatinine concentration. During six 
months of observation, patient with severe hyponatremia had repeated attack of 
dyspnea when compared with mild hyponatremia. The main observation is  sodium 
concentration in patient with ADHF is inversely related to serum creatinine 
concentration 
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                                            CONCLUSION 
            Heart failure is  the most common chronic heart related conditions in the 
developed countrys. It is characterized by  specific  neurohormonal activation of 
multiple  interrelated  systems that can lead to clinical worsening and significant 
morbidity and mortality. In this regard, hyponatremia occurs due to inappropriate 
and continued activity of vasopressin  despite hypoosmolality and volume 
overload. Hyponatremia is also due to diuretic use in an attempt to treat  volume 
overload. When hyponatremia occurs, it is a marker of heart failure severity and 
identifies patients with increased mortality. When the patient with presented with 
rish factors for CRS 1, renal failure develops.so, hyponatremia leads to  CRS 1 .  
           The recent introduction of specific vasopressin-receptor antagonists oers a 
targeted treatment to these pathophysiological derangements. Some  clinical trials 
with AVP-receptor antagonists have demonstrated an increase in free-water 
excretion, improvement in serum sodium, modest improvements in dyspnea . 
So,frequent monitoring of eletrolytes is the important step in the management of 
heart failure.  
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                                                  SUMMARY 
           Hyponatraemia  is the most common electrolyte disturbance in hospitalized 
patients in different clinical settings, and is commonly observed in patient with 
ADHF. It is more common in hospitalized patients with worsening heart failure 
than in outpatients. .Heartfailure-associated hyponatraemia is frequently 
hypervolaemic with both body sodium and water are  in excess, but the  water  
exeeds  sodium.Therefore,hypervolaemic hyponatraemia is a marker of congestion. 
             The volume overload  can  predispose to WRF, via several mechanisms 
such as tissue oedema and intra-abdominal hypertension. Another explanation  is 
general neurohumoral activation  including non-osmotic release of vasopressin, 
and increased levels of plasma renin, angiotensin II, aldosterone, and 
catecholamines and  directly affect renal haemodynamics. 
 The treatment is mainly based on  
• optimization of cardiac function by using beta blockers, ACE inhibitors or 
ARBs,  
• preservation of renal function by blood pressure control, avoiding 
nephrotoxic drugs,contrast dye and excessive diuresis,  
• maintaining appropriate fluid intake by frequent monitoring of eletrolytes 
• using vasopressin antagonists. 
        This study support the concept that hyponatremia is the important risk 
factor for cardiorenal syndrome type 1 in patients with ADHF. 
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LIMITATION OF STUDY 
 
• Hyponatremia is independent risk ractor for all system failures. 
• This study was conducted in only in tertiary level hospital 
• Smaller study group 
• The study population involved patients seeking medical care in a tertiary 
care   centre and hence may not represent the general population 
• Patient observation was done only for six months 
• This study only tell about morbidity of the patient not mortality. 
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PROFORMA 
 
Name: 
Age / Sex: 
Occupation: 
Presenting complaints: 
Past History: 
H/o DM, HT, CKD, CVD, NSAID INTAKE, CAD 
Clinical Examination: 
General Examination: 
Consciousness, 
Pallor, 
Jaundice, 
Clubbing, 
Lymphadenopathy, 
Hydration status, 
Pedal edema 
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Vitals: 
PR 
BP 
RR 
SpO2 
 
Systemic examination: 
CVS: 
 
RS: 
 
ABDOMEN: 
 
      CNS: 
Laboratory investigations: 
a)Complete blood count, 
b)Renal function test 
c)Urine routine, 
d)Serum electrolyte, 
e)Electrocardiogram, 
f)Echo 
g)USG abdomen 
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    KEY TO MASTER CHART 
     ARR---  Arrthythmia 
     AN---anemia 
CA---coronary artery disease 
CR---creatinine 
DCM---dilated cardiomyopathy 
DM---diabetes mellitus 
EF---ejection fraction 
GFR---estimated glomerular filtration rate 
GEN---gender 
HE---height 
HT---hypertension 
ME---medication 
MYO---myocarditis 
NA---sodium 
VHD---valvular heart disease 
WT ---weight 
 
 
 
                                                  
                                                   
S.N NAME 
    
HE WT   AG GEN AN ME DM HT CA VHD DCM MYO ARR 
 
EF% 
ADMISSION 3 MONTHS 6 MONTHS 
NA CR GFR NA CR GFR NA CR GFR 
1 ganesan 142 55 52 m A P P P P A A A A 42 128 2.2 36.5 133 1.8 44.6 139 1.1 73 
2 danapalan 155 63 67 m A P A A P A P A A 35 125 2.9 26.3 129 2.5 30.5 140 0.9 84.8 
3 jeyaraman 172 61 68 m P P P A P A A A A 47 130 2.3 31.7 133 2.1 34.7 141 0.8 91.1 
4 saroja 165 59 58 f A P A P P A P A A 47 131 2.2 31 128 2.8 24.3 139 1.1 62.06 
5 maniselvi 140 43 39 f P P A A A P A A P 41 127 3.1 19.8 130 2.8 21.89 140 1.2 51.07 
6 raja 148 51 51 m A P P P A A P A A 49 125 2.9 26.1 130 2.7 27.98 137 0.8 94.43 
7 muthu 168 67 48 m A A A P A A A A A 50 134 2.6 39.5 128 3.4 30.17 138 0.9 113.99 
8 mani 145 47 35 m A A P A A A A P A 49 133 2.7 30.4 130 3.1 26.5 141 0.9 91.3 
9 ramasamy 150 57 61 m A P P P P A A A A 29 130 2.8 26.8 122 3.5 21.4 135 1.1 68.13 
10 kandhasamy 157 65 71 m P P A P P A P A A 33 131 2.5 29.9 122 3.2 23.33 136 1.4 53.3 
11 saraswathy 140 45 35 f P P A A A P A A P 38 131 2.8 23.9 124 3.3 20.3 137 1.3 51.42 
12 lakshmi 131 40 27 f P A A A A P A A A 55 130 2.7 23.7 125 3.2 20 139 1.1 58.13 
13 raman 151 49 61 m P P P P A A A A A 49 131 2.6 24.9 128 3.1 20.8 137 1.1 58.73 
14 saradha 140 45 54 f A P P A A P A A A 39 129 3.1 17.7 125 3.6 15.3 135 1.1 49.9 
15 radha 135 41 21 f P P A A A P A A A 42 128 3.4 20.4 134 2.5 27.7 139 1.4 49.43 
16 sankar 164 71 56 m A A P P A A P A A 54 130 3.3 30.2 128 2.9 34.32 136 1.2 82.94 
17 kannan 157 58 61 m P A P P P A A A A 46 124 3.4 22.5 133 2.8 27.3 137 1.3 58.8 
18 karupayee 152 62 45 f P A A A P A A A A 37 120 3.6 23.2 128 3.1 27 135 1.4 59.68 
19 mathi 170 68 58 m A P P P A A P A P 44 119 3.5 26.6 127 2.9 32.1 134 1.3 71.6 
20 arivuselvi 155 61 53 f P A A P A A A A P 50 118 3.6 20.9 125 2.8 26.9 143 1.1 68.4 
21 gokul 151 49 68 m A P P A P A A A A 41 125 3.3 17.8 130 2.9 20.3 136 0.9 65.4 
22 arunachalam 149 61 53 m A P P P P A A A A 39 132 2.1 42.1 128 2.5 35.4 140 0.9 98.4 
23 sumathy 157 59 46 f A P P A A A A A A 49 119 2.7 29.1 125 2.1 37.5 142 0.8 98.3 
24 samy 153 65 57 m P A P P P A A A P 37 128 2.4 37.5 116 2.8 32.1 139 0.9 100.03 
25 vinitha 142 40 18 f A A A A A P A A A 50 126 2.5 27.7 132 2.2 31.5 139 1.1 62.9 
   
 
 
 
26 vijay 156 47 24 m A P A A A P A A A 42 125 2.9 31.4 129 2.5 36.4 140 1.3 70 
27 sethupathy 158 69 53 m A A A P P A A A A 35 131 2.2 45.5 128 2.8 35.8 137 1.3 77.06 
28 ramkumar 142 43 57 m A P P P A A P A A 48 127 3.1 19.2 130 2.7 22.06 140 1.2 49.63 
29 monisha 149 42 21 f P A A A A P A A P 47 130 3.3 21.5 128 2.9 24.5 136 1.2 59.1 
30 nithya 157 35 35 f A P A A A A A P A 37 124 3.4 15.3 133 2.8 18.6 137 1.1 47.4 
31 ajith 158 43 21 m A A A A A P A A A 41 121 2.9 30.1 130 2.5 34.9 140 1.1 79.5 
32 kamala 165 60 68 f A P P P A A P A A 45 120 3.3 18.6 125 2.8 21.9 139 1.3 47.1 
33 kumar 158 45 57 m A A A P P A A A A 48 123 3.3 18.9 131 2.9 21.5 136 0.9 69.3 
34 gurusamy 164 46 51 m A P P A A A A A P 50 123 2.9 23.6 129 2.5 27.3 140 1.2 56.9 
35 perumal 153 58 43 m A P P P P A A A A 44 127 3.3 28.5 118 2.9 32.4 138 1.4 67.1 
36 gunasekar 158 62 41 m A P A A A A P A A 49 124 3.1 33 133 2.8 36.6 137 1.4 73.2 
37 tamil 169 68 58 f P P P P A P A A A 33 125 2.9 27.3 129 2.5 31.6 140 1.2 65.9 
38 meenatchi 157 62 53 f A A P A P A A A A 49 121 2.7 28.3 125 2.1 36.4 142 0.8 95.6 
39 dharani 159 45 29 f A A P A A A A A A 48 129 2.4 29.5 116 2.8 25.3 139 0.9 78.7 
40 jaiganesh 164 70 54 m P A A P P A A A A 29 125 2.9 34.6 130 2.5 40.2 140 1.1 91.3 
41 balaji 157 58 58 m A P P P P A P A A 25 123 2.1 37.8 130 2.5 31.8 140 0.9 88.2 
42 balasudharam 154 49 52 m A A P A P A A A A 50 120 2.7 26.7 124 2.1 34.3 142 0.8 89.95 
43 anantd 168 61 54 m A P A P A A A A A 49 130 2.4 36.5 116 2.8 31.3 139 0.9 97.3 
44 rani 168 67 56 f P A A P P A P A P 40 126 2.5 31.9 132 2.1 38.01 139 1.1 72.6 
45 prabakar 148 55 64 m P P P P A A P A A 32 125 2.8 24.9 129 2.5 27.9 140 1.1 63.4 
46 marimuthu 156 69 67 m P A P A P A A A A 48 116 3.3 25.5 125 2.8 30 133 1.3 64.7 
47 ramalakshmi 148 58 62 f P P A P A A A A A 47 126 3.3 19.5 130 2.9 22.1 136 0.9 71.3 
48 balakumar 165 70 61 m A A P A P A A A P 50 125 2.9 31.8 129 2.5 36.9 148 1.3 71 
49 sudha 155 59 49 f A P P P A A P A A 35 131 2.2 34.6 128 2.8 27.2 135 1.3 58.6 
50 sudhasan 144 52 46 m A A P A P A A A A 40 127 3.1 26.3 130 2.5 32.6 142 0.9 90.6 
51 lokesh 171 65 48 m A P P P P A A A A 44 130 3.3 24.5 128 2.9 27.9 136 1.5 53.9 
52 kannagi 175 70 57 f A A P A A A P A A 46 124 3.4 19.7 133 2.8 23.9 137 1.5 44.5 
53 selvam 145 65 49 m A P A P P A A A A 39 120 3.6 22.2 125 2.8 28.6 136 1.1 72.74 
54 yasodha 165 61 68 f P A A A A A A P A 48 127 3.4 14.9 134 2.4 21 139 1.1 45.9 
55 begam 149 55 48 f P P P A P A A A A 30 121 2.9 20.1 125 2.7 21.6 136 1.1 52.9 
56 ramesh 158 67 57 m A A A P A A A A A 32 129 3.3 22.8 130 2.9 25.9 136 0.9 83.6 
57 amutha 157 60 68 f A P P P P A A A A 30 118 3.6 13.8 125 2.6 19.1 133 1.1 45.2 
58 ramprabhahar 159 64 49 m A P P P A A A A P 32 131 2.7 29.2 126 2.1 37.5 142 0.8 98.5 
59 srinivasan 167 69 51 m A A A A P A P A A 47 129 2.4 34.6 125 2.8 29.7 139 0.9 92.3 
60 marisevi 166 59 53 f A A P P A A A A P 44 121 3.6 16.4 128 2.8 26.6 136 1.5 39.4 
61 murali 165 65 65 m A P P P P A P A A 30 130 3.3 20 133 2.9 28.7 136 1.5 43.96 
62 manokar 158 62 58 m A P P A P A A A A 36 124 3.4 20.2 130 2.8 31.1 137 1.5 45.9 
63 praveen 168 70 53 m P P P A P A A A A 46 125 2.9 28.4 132 2.5 41.6 140 1.1 74.9 
64 sugadev 149 55 52 m A P A P A A A A A 49 120 3.6 18.2 127 2.8 29.5 133 1.1 59.5 
65 manoj 158 60 68 m A A P A P A A A P 42 134 2.6 22.5 130 3.4 21.7 138 1.9 30.8 
66 karuppasamy 157 68 69 m A P P P A A A A A 49 133 2.7 24.2 127 3.1 26.6 141 0.9 72.6 
67 leela 169 55 64 f A P A P P A P A A 39 130 2.8 17.2 129 3.5 17.4 135 1.3 37 
68 nirmala 159 60 48 f P P P A P A A A A 44 118 3.3 19.2 124 2.8 28.6 133 1.2 52.9 
69 devi 157 58 49 f A A P P P A P A P 36 132 2.1 29 121 2.5 30.7 140 0.9 67.4 
70 priya 145 53 43 f P A P P A P A A A 34 119 2.7 21.9 130 2.1 35.5 142 0.8 73.9 
71 hemalatha 158 57 47 f A A A A P A P A P 35 128 2.4 25.4 122 2.8 27.5 139 0.9 67.7 
72 natarajan 168 69 58 m P P P P P A A A A 31 128 2.5 30.6 133 2.2 43.9 139 1.1 69.6 
73 nagarajan 168 67 51 m A A A P P A P A P 38 125 2.7 29.9 128 2.5 40.7 140 1.3 62.1 
74 nathiya 162 64 53 f P A P P P A A A P 28 118 3.6 17.8 125 2.7 29.9 133 0.9 71.1 
75 yamuna 163 62 67 f A P P A P A A A A 46 118 3.3 15.8 123 2.8 23.5 133 0.6 86.7 
76 krishnan 152 59 60 m A A P P P A A A A 37 125 2.8 22.8 131 1.9 42.4 136 0.9 70.9 
77 subbulakshmi 153 60 50 f P P A P P A A A A 49 118 3.2 19.4 124 2.8 28.1 133 1.1 56.5 
78 ramamoorthy 157 64 50 m A A P P A A P A A 50 131 2.2 35.4 120 2.8 35.2 135 1.5 51.9 
79 bramman 166 70 55 m P A P A P A A A A 45 127 3.1 26 130 2.7 37.6 139 1.3 61.9 
80 sathyan 170 74 44 m A A P P P A A A A 25 132 2.1 45.8 127 2.4 50.6 140 0.9 106.7 
81 jeyaprakash 158 60 58 m A P P A P A A A A 48 119 2.7 24.7 127 2.1 40.2 142 0.8 83.2 
82 pothiraj 158 68 54 m A P A A P A A A A 48 128 2.4 33 119 2.8 35.7 139 0.9 87.9 
83 lavanya 147 58 53 f A P P P P A P A P 32 126 2.5 23.2 131 1.8 40.7 139 1.1 52.8 
84 sugumar 168 65 51 m A A P A P A P A A 40 118 3.2 24.5 124 2.8 35.2 137 1.1 71.1 
85 saravanan 168 63 68 m P A A A P A A A A 42 132 2.1 30 125 2.5 30.9 140 0.9 70 
86 maya 150 45 20 f A A A A A P A A A 50 119 2.4 26.6 130 2.1 37.3 142 0.8 79.7 
87 rajakumari 155 50 29 f P A A A A P A A P 40 118 3.6 18.2 127 2.8 28.8 133 1.1 59.5 
88 muthukrishnan 155 54 49 m A A A P A A A A A 35 125 3.3 20.7 132 1.9 44.2 136 0.9 75.8 
89 kannusamy 144 50 68 m A A A P P A A A A 39 118 2.9 17.2 124 2.5 24.6 136 1.5 33.3 
90 sundhari 162 60 57 f P A P A P A A A A 37 134 2.6 22.6 122 3.4 21.3 138 1.9 30.9 
91 kumari 153 68 58 f A P P A A A P A A 34 133 1.7 38.7 121 3.1 26.1 141 0.9 73.1 
92 divya 150 72 31 f A A A A A A A P A 50 130 2.8 33.1 123 3.5 32.5 139 1.1 84.2 
93 prabu 177 75 66 m A P P P P A A A A 47 125 2.9 26.6 132 2.5 37.9 140 1.3 59.3 
94 sathyan 166 65 55 m A P P P P A A A A 25 118 3.6 21.3 125 2.8 33.7 138 1.1 69.7 
95 hema 158 55 28 f P P A A A P A A P 45 133 2.1 34.6 121 2.5 35.7 140 0.9 80.8 
96 rajasekar 148 50 40 m A A P P P A A A A 29 119 2.7 25.7 129 2.1 40.7 142 0.8 86.8 
97 rajesh 153 51 49 m A P A P A A A A A 30 130 2.4 26.9 120 2.8 28.3 139 0.9 71.6 
98 rajathi 146 48 48 f P P P A P A P A A 31 126 2.5 20.9 131 2.1 30.5 139 1.1 47.4 
99 senthil 169 68 60 m A A P P A A A A A 32 120 3.6 21 125 2.8 33.2 133 1.5 50.4 
100 ramajeyam 175 74 57 m A P P A P A A A P 25 124 2.9 29.4 131 2.5 41.9 140 1.1 77.5 
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